SK Bioscience received an A grade or higher in all categories in the 2022 ESG evaluation and rating announcement results for listed companies announced by the Korea ESG Standards Service (KCGS). In particular, it received the industry’s highest level rating in the first ESG evaluation after its launch, and is receiving attention for being recognized for its sustainable growth and advanced management system performance.
SK Bioscience earned an A+ grade in the social sector and an A grade in the environment and governance sector in recognition of its efforts to create social value through its own development of a COVID-19 vaccine and to publish the first ESG report this year.
In particular, this year is the first year that KCGS has increased the difficulty of evaluation questions in all areas of environment, society, and governance by reflecting the latest global ESG trends, and SK Bioscience is making efforts to create social and economic values and enhance its management system. This result was achieved with recognition.
In detail, it received positive evaluations in areas such as promoting human health through vaccine development, pursuing happiness of stakeholders such as members, and complying with strict global regulations during the vaccine development process. In addition, it was highly evaluated that it contributed to solving social problems through various local social contribution activities and established a sustainable management system by disclosing ESG management information through ESG reports and laying the foundation for board-centered management.
SK Bioscience plans to further strengthen ESG management activities for sustainable growth in the future. To this end, in the environmental field, ▲advancing the environmental management system ▲responding to climate change by realizing Net Zero, and in the social field, ▲expanding talent and human rights management ▲creating social value (SV) in the community ▲creating SV through business ▲establishing a global bio ecosystem, In the governance area, we are establishing and implementing eight strategic goal plans, including internalizing ESG management and strengthening board-centered management.
In addition, in line with the advanced global ESG management environment, SK Bioscience acquired the international certification ISO14001 for the environmental management system of Andong L House, a vaccine production facility, this month, and completed the establishment of a human rights management declaration to pursue the continuous happiness of members and stakeholders. did.
In the future, we plan to ▲establish a climate change response strategy and carbon neutrality roadmap ▲publish a Taskforce on Climate-related Financial Disclosures (TCFD) report within the year. We will also conduct human rights impact assessments, establish codes of conduct for partner companies, and establish supply chain ESG management strategies and systems.
Jae-yong Ahn, President of SK Bioscience, said, “The results of this evaluation are the result of the efforts of all members and stakeholders to fulfill their responsibilities in the two areas of promoting human health and social responsibility.” He added, “We will not be complacent with the status quo and will advance our business and management environment. “We will strive to achieve sustainable growth by actively communicating with stakeholders.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news